MedReps
Pharmaceutical sales recruiters are keeping a close eye on Cornerstone Therapeutics after a clinical reviewer recommended that the Food and Drug Administration (FDA) approve the company's new low salt drug, lixivaptan.
Cornerstone (CRTX) Tumbles After FDA Committee Votes Against Hyponatremia ... iStockAnalyst
Cornerstone:FDA Panel Votes Against Approval Of Lixivaptan To Treat Hyponatremia
Restaurant foods for takeout, catering, business meetings, team lunches, conferences, and sporting events.